OUR TEAM

Gentronix Ltd. comprises a team of people who are passionate about the science of toxicology. Combined, we have decades of experience within predictive toxicology space and the SME environment and together we are committed to delivering the highest quality science, in an effective and efficient manner.

A WEALTH OF EXPERIENCE

ALAN MORGAN
ALAN MORGANChairman
As Chairman of the Board, Alan provides leadership to the Board of Directors and strategic input into the growth and delivery of the business. Alan has a wealth of experience in scaling service businesses, gained over 20 years from senior executive roles within major CROs. Alan also has extensive experience of raising growth capital and delivering buy and build strategies with support of private equity.
MATT TATE
MATT TATEManaging Director
Matt has been with the business for over 12 years. Initially working on the development of our screening assays and earning a PhD in genetic toxicology, Matt transitioned to the commercial side of the business, working globally with clients to implement the most appropriate testing strategies for their needs. He now leads the business, developing our overall strategy and delivering our plan to build an expert predictive toxicology CRO, whilst remaining passionate about toxicology and engaging with our clients to meet their challenges.
NICK BILLINTON
NICK BILLINTONOperations Director
Nick is one of the company’s originating scientists, initially as a PhD student in the founding lab. Post-PhD, Nick led the research efforts to develop the GreenScreen® HC & BlueScreen™ HC technologies, and then the transition of the business to a CRO. Providing project management and scientific leadership, Nick implemented GLP compliance in the organisation. As Operations Director, Nick continues to ensure our commitment to expert delivery of high quality science is maintained.
PAUL RAWLINSON
PAUL RAWLINSONLead Toxicologist
Paul recently joined Gentronix after working as a general and genetic toxicologist at a major agrochemical R&D company for 11 years. Prior to that he had experience in the cosmetics industry and in pharmaceutical literature services. Paul’s skills and experience includes designing testing strategies, data interpretation, product development and regulatory product safety advocacy.
JOHN YATES
JOHN YATESFinancial Director
John is a highly experienced Financial Director, with an extensive track record in supporting the financial management of SME sector organisations. John qualified as a Chartered Accountant at KPMG, and then spent several years in industry before establishing his own consultancy practice via which he worked at Board level for various technology-based businesses both in the UK, Europe and the USA. During this time, he has acted in a series of funding transactions and has also participated in a number of company disposals. He joined the Board of Gentronix Limited 2001, and has been Finance Director from 2004. He also acts as the Company Secretary.
CHRIS MEESenior Study Director
Chris joined Gentronix in 2013 and is the Senior Study Director within the business. Chris has 45 years’ experience in Genetic Toxicology having previously worked for leading global pharmaceutical and R&D companies. Initially joining Gentronix to introduce the Bacterial Reverse Mutation Assay (Ames test) and implementation of GLP compliance in the organisation; Chris now provides expert training, guidance and mentoring to Study Directors within the company as well as leading the Ames testing activities.
JODIE BALLStudy Director
Jodie joined Gentronix in 2011 and is a Study Director for skin sensitisation testing. Having completed a PhD in cancer biology, Jodie joined Gentronix as part of the genetic toxicology screening services team, progressing to leading that team. Since 2017, she has been involved in the implementation of skin toxicology assays, for which she is now Study Director.
KATIE CLAREStudy Director
Katie joined the company in 2015 and is a cytogenetics and gene mutation Study Director. Prior to joining Gentronix, Katie worked in the Genetic Toxicology department of a leading pharmaceutical company for over 20 years, gaining extensive experience in performance and interpretation of GLP Genetic Toxicology studies.
EMMA GOODHEADStudy Director
Emma joined Gentronix in 2016 and is currently a Study Director for bacterial reverse mutation (Ames Test) assays. She is an experienced genetic toxicologist having worked for >25 years in GLP-compliant laboratories carrying out genetic toxicology assays including cytogenetic assays, the bacterial reverse mutation assay (Ames test), mammalian gene mutation and Comet assay endpoints.
JULIE HAYESStudy Director
Julie joined the company in 2018, as a Study Director specialising in cytogenetics assays. Prior to this, Julie had worked in the Genetic Toxicology Department of a leading pharmaceutical company for 26 years holding positions as a senior cytogeneticist, GLP Study Director and latterly as a Study Monitor. Julie’s current role within Gentronix is as a Study Director for cytogenetic assays and as the Project Licence Holder.
EMILY SMITHStudy Director
Emily joined the company in 2018 and is currently Study Director for Genetic Toxicology Screening. Prior to joining Gentronix, Emily completed a PhD and academic research position performing in vitro assays to screen and repurpose compounds for potential treatments of inflammatory bowel disease. Since joining the business Emily has become proficient in the range of assays carried out in the screening and skin sensitization laboratories, and now is Study Director for screening services.
JO WALKERStudy Director
Jo joined Gentronix in 2014 and is a Study Director for cytogenetic assays. Jo has over 20 years of Genetic Toxicology experience having previously worked within the Genetic Toxicology department of a leading pharmaceutical company. Since joining the business, initially as a Study Investigator, Jo progressed to the role of Study Director and now leads our screening cytogenetics team.

OUR VALUES

OUR VALUES

Our business origins are in the delivery of innovative screening products for toxicological hazard; challenging the established approach with scientific rigour. Building on our experiences of developing market leading predictive toxicology assays, we have extended our expertise to the regulatory tests for genetic toxicology and recently skin sensitisation.

We make a commitment to our clients to perform toxicology studies of the highest scientific quality; not merely to produce data, but to deliver the most appropriate data endpoints, using the right assay tools, guided by scientific engagement and experience. Furthermore, we are committed to helping our clients understand and interpret their results, supporting navigation of regulatory landscapes and management of adverse toxicology findings.

This is guided by our core values, which we apply to all the studies we perform:

  • Excellence; we strive to deliver the highest quality service using the most appropriate scientific tools.
  • Effectiveness; we aim to deliver high quality results when you need them.
  • Efficiency; we optimise our approach to deliver maximum data from minimum material.
  • Engagement; we engage scientifically to support study design through to data interpretation and management.

Our business origins are in the delivery of innovative screening products for toxicological hazard; challenging the established approach with scientific rigour. Building on our experiences of developing market leading predictive toxicology assays, we have extended our expertise to the regulatory tests for genetic toxicology and recently skin sensitisation.

We make a commitment to our clients to perform toxicology studies of the highest scientific quality; not merely to produce data, but to deliver the most appropriate data endpoints, using the right assay tools, guided by scientific engagement and experience. Furthermore, we are committed to helping our clients understand and interpret their results, supporting navigation of regulatory landscapes and management of adverse toxicology findings.

This is guided by our core values, which we apply to all the studies we perform:

  • Excellence; we strive to deliver the highest quality service using the most appropriate scientific tools.

  • Effectiveness; we aim to deliver high quality results when you need them.

  • Efficiency; we optimise our approach to deliver maximum data from minimum material.

  • Engagement; we engage scientifically to support study design through to data interpretation and management.

SCREENING & SAFETY

Erlenmeyer Flask to represent predictive genotoxicity screening

Predictive Genotoxicity Screening

We offer a broad range of rapid turnaround screens, focussed on low test item usage, to detect and contextualise genotoxic liability early in development.

Find out more
test tubes to represent regulatory studies

Regulatory Genotoxicity Studies

We offer GLP Ames, mouse lymphoma and in vitro micronucleus studies that allow clients to demonstrate chemical safety and address their regulatory requirements.

Find out more
skin sensitisation icon representing the skin sensitisation aop

Skin Sensitisation

Providing DPRA, KeratinoSensTM and h-CLAT assays, we enable several key events of the skin sensitisation adverse outcome pathway to be assessed.

Find out more
icon depicting gentronix flow cytometry services

Flow Cytometry Services

Working with our clients, we utilise our flow cytometry experience and expertise to deliver a diverse range of endpoints.

Find out more

Predictive Toxicology, Expertly Delivered

GET IN TOUCH